BackgroundCheck.run
Search For

Andrew Te Parkinson, 6918000 W 68Th St, Shawnee Mission, KS 66217

Known as:
Andrew D Parkinson Andy Parkinson
Related to:
Courtney Marie Wilson 41

Andrew Parkinson Phones & Addresses

18000 W 68Th St, Shawnee, KS 66217    913-6311052   

7538 Mohawk St, Prairie Village, KS 66208    913-6487945   

Lenexa, KS   

Shawnee Msn, KS   

Prairie Vlg, KS   

Social networks

Andrew Te Parkinson

Linkedin

Work

Company: Clara biotech Jul 2019 Position: Advisor

Education

Degree: Doctorates, Doctor of Philosophy School / High School: University of Guelph 1977 to 1981 Specialities: Chemistry

Skills

Drug Discovery • Drug Metabolism • Life Sciences • Pharmacology • Glp • Pharmaceutical Industry • Pharmacokinetics • Biotechnology • Dmpk • In Vitro • Biochemistry • Adme • Cro • Toxicology • Clinical Development • Cell Culture • Hplc • Molecular Biology • Drug Development • Bioanalysis • Lifesciences • Lc Ms • Cell Biology • Cell • Mass Spectrometry • Fda • Cancer • Protein Chemistry • In Vitro Toxicology • Validation • R&D • Science • Biopharmaceuticals • Lead Change • Cell Based Assays • Lims • Pharmaceuticals • Lead Optimization • Ind • Drug Design • Therapeutics • Pharmaceutical Research • Clinical Pharmacology • Genomics • Automation

Industries

Pharmaceuticals
Get Report
Control this profile

Mentions for Andrew Te Parkinson

Career records & work history

Medicine Doctors

Andrew B. Parkinson

Specialties:
Orthopaedic Surgery, Orthopaedic Surgery Of Spine
Work:
Orthopedic Associates Inc
3301 NW 50 St, Oklahoma City, OK 73112
405-9470911 (phone) 405-9471341 (fax)
Site
Education:
Medical School
University of Southern California Keck School of Medicine
Graduated: 2002
Procedures:
Arthrocentesis, Spinal Cord Surgery, Spinal Fusion, Spinal Surgery
Conditions:
Fractures, Dislocations, Derangement, and Sprains, Internal Derangement of Knee Cartilage, Intervertebral Disc Degeneration, Osteoarthritis, Plantar Fascitis, Rotator Cuff Syndrome and Allied Disorders, Sciatica, Scoliosis or Kyphoscoliosis, Spinal Stenosis
Languages:
English, Spanish
Description:
Dr. Parkinson graduated from the University of Southern California Keck School of Medicine in 2002. He works in Oklahoma City, OK and specializes in Orthopaedic Surgery and Orthopaedic Surgery Of Spine. Dr. Parkinson is affiliated with Deaconess Hospital, Integris Baptist Medical Center and Oklahoma Spine Hospital.
Andrew Parkinson Photo 1

Andrew Benjamin Parkinson

Specialties:
Orthopaedic Surgery
Orthopaedic Surgery of the Spine
Education:
University of Southern California(2002)

Andrew Parkinson resumes & CV records

Resumes

Andrew Parkinson Photo 40

Advisor

Location:
Shawnee, KS
Industry:
Pharmaceuticals
Work:
Clara Biotech
Advisor Xpd Consulting
Chief Executive Officer Xenotech 1994 - 2011
Chief Scientific Officer University of Kansas Medical Center 1982 - 2000
Professor
Education:
University of Guelph 1977 - 1981
Doctorates, Doctor of Philosophy, Chemistry University of Surrey 1973 - 1977
Bachelors, Bachelor of Science, Biochemistry
Skills:
Drug Discovery, Drug Metabolism, Life Sciences, Pharmacology, Glp, Pharmaceutical Industry, Pharmacokinetics, Biotechnology, Dmpk, In Vitro, Biochemistry, Adme, Cro, Toxicology, Clinical Development, Cell Culture, Hplc, Molecular Biology, Drug Development, Bioanalysis, Lifesciences, Lc Ms, Cell Biology, Cell, Mass Spectrometry, Fda, Cancer, Protein Chemistry, In Vitro Toxicology, Validation, R&D, Science, Biopharmaceuticals, Lead Change, Cell Based Assays, Lims, Pharmaceuticals, Lead Optimization, Ind, Drug Design, Therapeutics, Pharmaceutical Research, Clinical Pharmacology, Genomics, Automation

Publications & IP owners

Us Patents

Ex Vivo Methods To Identify Circulating Drug Metabolites With Drug Interaction Potential

US Patent:
2013033, Dec 12, 2013
Filed:
Jun 11, 2013
Appl. No.:
13/915392
Inventors:
Andrew Parkinson - Shawnee KS, US
International Classification:
C12Q 1/26
US Classification:
435 613, 435 25, 435 792, 435 71
Abstract:
Ex vivo methods of detecting and analyzing circulating drug metabolites with drug interaction potential are provided. The methods include the use of clinical plasma samples from subjects who have been administered an investigational drug in vivo. The clinical plasma samples will contain both the parent drug and associated metabolites. A control plasma sample spiked directly with the drug of interest can be used as a standard reference. The plasma samples can be applied to an in vitro test system to evaluate the changes in activity or expression of drug-metabolizing enzymes and/or drug transporters in the test systems to determine circulating drug metabolites with drug interaction potential. By comparing the clinical plasma sample to the drug-spiked control, the inhibitory and/or inducing effects on drug-metabolizing enzymes and/or drug transporters can be correctly attributed to the parent drug or its associated metabolites.

Method And Apparatus For Determining The Role Of Cytochrome P450 And Related Enzymes In The Metabolism Of Drugs And Other Chemicals

US Patent:
5478723, Dec 26, 1995
Filed:
Sep 27, 1993
Appl. No.:
8/127317
Inventors:
Andrew Parkinson - Prairie Village KS
Dorn C. Cook - Tempe AZ
International Classification:
C12Q 100
C12Q 126
C12N 902
G01N 33483
US Classification:
435 4
Abstract:
A method and apparatus for determining the enzyme or enzymes in the human body which metabolize a particular drug. Microsomes are obtained from each of several donors. The microsome for one donor is reacted with a test drug and the quantity of metabolites produced is determined. The microsomes are similarly each reacted with the test drug and the quantity of metabolites produced for each microsome is determined to generate drug metabolism data. The drug metabolism data obtained is compared to reference data which indicates the activity of a select number of major enzymes in each of the donors. The reference data for each enzyme is separately tabulated. The enzyme responsible for the metabolism of the test drug is identified when the metabolism data correlates with the tabulated reference data for that enzyme.

Combination Of Pimavanserin And Cytochrome P450 Modulators

US Patent:
2020007, Mar 12, 2020
Filed:
Nov 15, 2019
Appl. No.:
16/684883
Inventors:
- San Diego CA, US
Andrew Parkinson - Shawnee KS, US
International Classification:
A61K 31/4468
A61P 25/28
A61P 25/18
A61P 25/24
A61P 25/16
A61K 9/00
A61K 45/06
Abstract:
A method for treating a disease or disorder in a patient who is currently taking a cytochrome P450 inhibitor comprising administering to the patient a dose of pimavanserin or a pharmaceutical acceptable salt thereof, wherein the dose is at least 20% lower than a dose of pimavanserin or a pharmaceutical acceptable salt thereof that would otherwise have been recommended to the patient if the patient were not currently taking the cytochrome P450 inhibitor.

Combination Of Pimavanserin And Cytochrome P450 Modulators

US Patent:
2019024, Aug 8, 2019
Filed:
Mar 23, 2017
Appl. No.:
16/087604
Inventors:
- San Diego CA, US
Andrew Parkinson - Shawnee KS, US
International Classification:
A61K 31/4468
A61K 9/20
A61P 25/16
A61P 25/28
A61P 25/18
A61K 45/06
Abstract:
A method for treating a disease or disorder in a patient who is currently taking a cytochrome P450 inhibitor comprising administering to the patient a dose of pimavanserin or a pharmaceutical acceptable salt thereof, wherein the dose is at least 20% lower than a dose of pimavanserin or a pharmaceutical acceptable salt thereof that would otherwise have been recommended to the patient if the patient were not currently taking the cytochrome P450 inhibitor.

Combination Of Pimavanserin And Cytochrome P450 Modulators

US Patent:
2019023, Aug 1, 2019
Filed:
Apr 9, 2019
Appl. No.:
16/379169
Inventors:
- San Diego CA, US
Andrew Parkinson - Shawnee KS, US
International Classification:
A61K 31/4468
A61P 25/24
A61P 25/16
A61P 25/18
A61P 25/28
Abstract:
A method for treating a disease or disorder in a patient who is currently taking a cytochrome P450 inhibitor comprising administering to the patient a dose of pimavanserin or a pharmaceutical acceptable salt thereof, wherein the dose is at least 20% lower than a dose of pimavanserin or a pharmaceutical acceptable salt thereof that would otherwise have been recommended to the patient if the patient were not currently taking the cytochrome P450 inhibitor.

Isbn (Books And Publications)

Cutting It Fine

Author:
Andrew Parkinson
ISBN #:
0224060775

Possible Relatives

David Parkinson  Dean B Parkinson  Dale Parkinson  Deborah L Parkinson  Daniel E Parkinson  Aaron Parkinson  Don P Parkinson  Andrew T Last  Andrew R Johnson  Andrew P Stanco 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.